Incyte Had a Bad Week. Investors Are Used to It.
Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...
Pharmaceutical giant Incyte will move into two of Wilmington's most iconic buildings
Bracebridge III, on North French Street, will be home to "future expansion" by Incyte. Wilmington Mayor Mike Purzycki thanked ...
Hosted on MSN1y
Delaware is the first state in the country to get a drug named after it, says Incyte CEO
Specifically, the First State may be the first state in the nation to have a generic drug named after it, said Incyte CEO Hervé ... Chamber of Commerce president Mike Quaranta noted that China's ...
pharmaphorum3y
FDA sets April date for verdict on Incyte's vitiligo drug
Opzelura is a topical version of Incyte's oral drug Jakafi/Jakavi, which is FDA approved for myelofibrosis, polycythaemia vera and graft-versus-host-disease, and has been billed as a major growth ...